Entero Therapeutics (ENTO) Stock Price, News & Analysis

Company Overview

Entero Therapeutics, Inc. (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development. By employing proprietary formulation platforms, the company seeks to optimize oral bioavailability and site‐specific release profiles, enabling precise treatment of localized GI pathology. Entero works closely with academic medical centers, clinical research organizations and patient advocacy groups to advance its programs through regulatory milestones, with the goal of delivering novel treatment options for both adult and pediatric patient populations.

Founded in 2018 and headquartered in Massachusetts, Entero Therapeutics operates with a network of partners and investigators across the United States. The company maintains a lean organizational structure to support focused development and commercialization activities in the GI space. Through disciplined clinical execution and strategic alliances, Entero aims to become a leading provider of specialized therapies that address significant unmet needs in gastrointestinal health.

Key Stats

• Today's Range: $5.06 to $5.97
• 50-Day Range: $2.06 to $6.80
• 52-Week Range: $0.32 to $5.84
• Volume: 80,803 shs
• Average Volume: 2.80 million shs
• Market Capitalization: $8.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Entero Therapeutics Stock Analysis - MarketRank™

Entero Therapeutics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Entero Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Entero Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Entero Therapeutics is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Entero Therapeutics is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ENTO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Entero Therapeutics does not currently pay a dividend.

Dividend Growth

Entero Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

Entero Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Entero Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Entero Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.75% of the stock of Entero Therapeutics is held by insiders.

Percentage Held by Institutions

12.30% of the stock of Entero Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 6/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENTO
• Previous Symbol: NASDAQ:ENTO
• CIK: 1604191
• Web: www.enterothera.com
• Phone: 561-589-7020
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.06 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -461.02%
• Return on Assets: -14.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.62
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.45) per share
• Price / Book: -2.15

Miscellaneous

• Outstanding Shares: 1,588,000
• Free Float: 3,337,000
• Market Cap: $8.37 million
• Optionable: N/A
• Beta: 1.19